U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Featured Journal Content


U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment


CDC – Coronavirus Disease 2019 (COVID-19) – Latest Updates
:: Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 19 Feb 2021 06:00:00 EST Friday, February 19, 2021


Vaccines and Related Biological Products Advisory Committee February 26, 2021 Meeting Announcement – 02/26/2021 – 02/26/2021
The committee will meet in open session to discuss EUA of the Janssen Biotech Inc. COVID-19 Vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years and older.

Vaccines and Related Biological Products Advisory Committee March 5, 2021 Meeting Announcement – 03/05/2021 – 03/05/2021
The Committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2021 – 2022 influenza season.

White House [U.S.]
Briefing Room
Fact Sheet: President Biden Announces New Actions to Expand and Improve COVID-19 Testing
February 17, 2021 • Statements and Releases
As the virus continues to spread throughout the world, and with new variants emerging, the facts are clear that it is critical that we vaccinate as many people as possible, as quickly as possible. Tomorrow at the G7, the President will announce that he is taking concrete steps to improve the health and the safety of Americans by protecting vulnerable populations worldwide. He will also call on G7 partners to prioritize a sustainable health security financing mechanism aimed at catalyzing countries to build the needed capacity to end this pandemic and prevent the next one.

COVID has shown us that no nation can act alone in the face of a pandemic. Today, President Biden is taking action to support the world’s most vulnerable and protect Americans from COVID-19.

Using money appropriated by a bipartisan Congressional vote in December 2020, the United States will provide an initial $2 billion contribution to Gavi, the Vaccine Alliance for the COVAX Advance Market Commitment, the innovative financing instrument of the COVAX Facility, which supports access to safe and effective vaccines for 92 low- and middle-income economies.

The United States will also take a leadership role in galvanizing further global contributions to COVAX by releasing an additional $2 billion through 2021 and 2022, of which the first $500 million will be made available when existing donor pledges are fulfilled and initial doses are delivered to AMC countries. In close cooperation with Gavi, this additional $2 billion in funding will serve to expand COVAX’s reach.  We also call on our G7 and other partners to work alongside Gavi, to bring in billions more in resources to support global COVID-19 vaccination, and to target urgent vaccine manufacturing, supply, and delivery needs.

Finally, at the G7 President Biden will reaffirm the U.S. commitment to global health security and advancing the Global Health Security Agenda.  All countries should have the capability to prevent, detect, and respond to outbreaks.  The COVID-19 pandemic and ongoing outbreaks of Ebola in the Democratic Republic of the Congo and Guinea highlight the need for sustainable health security financing to catalyze country capacity to prevent biological catastrophes…

Statement by National Security Advisor Jake Sullivan
February 13, 2021
The mission of the World Health Organization (WHO) has never been more important, and we have deep respect for its experts and the work they are doing every day to fight the COVID-19 pandemic and advance global health and health security. That is why President Biden rejected and reversed the Trump Administration’s decision to disengage from the WHO. But re-engaging the WHO also means holding it to the highest standards.  And at this critical moment, protecting the WHO’s credibility is a paramount priority. We have deep concerns about the way in which the early findings of the COVID-19 investigation were communicated and questions about the process used to reach them. It is imperative that this report be independent, with expert findings free from intervention or alteration by the Chinese government. To better understand this pandemic and prepare for the next one, China must make available its data from the earliest days of the outbreak. Going forward, all countries, including China, should participate in a transparent and robust process for preventing and responding to health emergencies — so that the world learns as much as possible as soon as possible.

Remarks by President Biden at Pfizer Manufacturing Site
February 19, 2021 • Statements and Releases

Press Briefing by White House COVID-19 Response Team and Public Health Officials
February 19, 2021 • Press Briefings

Fact Sheet: President Biden to Take Action on Global Health through Support of COVAX and Calling for Health Security Financing
February 18, 2021 • Statements and Releases

Press Briefing by White House COVID-19 Response Team and Public Health Officials
February 17, 2021 • Press Briefings

Statement by White House Press Secretary Jen Psaki on Cases of Ebola
February 16, 2021 • Statements and Releases